Clinical Trials – The Importance of Diversity in Clinical Trials

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Clinical trials help us assess the safety and effectiveness of upcoming or existing therapeutics. The clinical trials turn out to be even more successful if the trial participants are representatives of the wider disease population. Lack of diversity in the clinical trial population often minimizes the quality of data obtained for drug safety and efficacy profiles. Furthermore, conducting clinical trials with a diverse demographic set-up ensures a better understanding and a more targeted approach to the administration of therapeutics while providing access to novel groundbreaking therapies in clinical trials.

This diversity in clinical trials market research report provides an analysis of clinical trial racial representation data and evaluates racial demographics across a number of clinical trial sectors to highlight the level of diversity.

Diversity in Clinical Trials – Barriers and Improvement Strategies

For diversity in trials to be improved, factors negatively influencing diversity must be recognized. A major barrier in effectively studying diversity in clinical trials is the low levels of race disclosure of study participants. Increased disclosure would allow for a more accurate assessment of race disparities in the clinical trial landscape.

Strategies to improve diversity across the Pharma industry must be considered where trial populations vastly differ from the disease demographics. Sponsors involved in trials should outline specific targets prior to enrolment to ensure the study population is representative of the disease populations. These targets should be communicated with investigators and primary healthcare providers to reduce the level of implicit bias during recruitment.

For more understanding of strategies to overcome challenges to diversity in clinical trials, download a free sample

Diversity in Clinical Trials Market by Region

The key regions in the clinical trials market are North America, South and Central America, Europe, Middle East and Africa, and Asia-Pacific, among others. North America and South and Central America lead the reporting of race data followed by Europe, Middle East and Africa, and Asia-Pacific, respectively as of July 2022.

Clinical Trials with Disclosed Racial Representation Data, by Region

Clinical Trials with Disclosed Racial Representation Data, by RegionFor more insights on diversity in clinical trials by region, download the free sample

Diversity in Clinical Trials Market by Country

The key countries in the clinical trials market with disclosed racial representation data are Canada, the US, Spain, Germany, France, the UK, Japan, China, India, and Iran among others. Canada had the highest percentage of clinical trials with disclosed racial representation data, followed by the US, Spain, and Germany.

Clinical Trials with Disclosed Racial Representation Data, by Country

Clinical Trials with Disclosed Racial Representation Data, by CountryFor more insights on the diversity in clinical trials by country, download the free sample

Diversity in Clinical Trials Market by Demography

The key demographic groups or study subjects in the clinical trials reporting race data are White, Black or African Americans, Asians, American Indian or Alaska Native, Mixed, and Native Hawaiian or Pacific Islander or Indigenous Australians. Globally, in clinical trials reporting race data, the overwhelming majority of study subjects are white.

Clinical Trials with Disclosed Racial Representation Data, by Demography

Clinical Trials with Disclosed Racial Representation Data, by DemographyFor more insights on the diversity in clinical trials by demography, download the free sample

Diversity in Clinical Trials Market by Sponsor Type

The key sponsor types in the clinical trials market are industry sponsors and institutional sponsors. Industry-sponsored trials have a greater proportion of white participants than institutional trials.

Clinical Trials with Disclosed Racial Representation Data, by Sponsor Type

Clinical Trials with Disclosed Racial Representation Data, by Sponsor TypeFor more information on sponsor types in the clinical trials market, download sample report

Diversity in Clinical Trials Market by Therapy Areas

The key therapy areas in the clinical trials market are Oncology, Central Nervous System Disorders, Infectious Diseases, Cardiovascular, and Metabolic Disorders. Of the top therapy areas, Oncology has the highest representation of Asian participants, with white participants forming the overall majority.

Clinical Trials with Disclosed Racial Representation Data, by Therapy Areas

Clinical Trials with Disclosed Racial Representation Data, by Therapy Areas

For more information on therapy types in the clinical trials market, download sample report

Diversity in Clinical Trials Market by Company

Some of the leading companies in the clinical trials market are Novartis, GSK, Pfizer, Johnson & Johnson, AstraZeneca, Eli Lily, F.Hoffmann-La Roche, Merck & Co, AbbVie, and Bayer among others. GSK showcases the most well- rounded diversity where the top three common racial groups are concerned.

Clinical Trials with Disclosed Racial Representation Data, by Company

Clinical Trials with Disclosed Racial Representation Data, by CompanyFor more information on diversity in companies in the clinical trials market, download the sample report

Diversity in Clinical Trials Market Overview

Key Regions North America, South and Central America, Europe, Middle East and Africa, and Asia-Pacific
Key Countries Canada, the US, Spain, Germany, France, the UK, Japan, China, India, and Iran among others
Key Demography White, Black or African Americans, Asians, American Indian or Alaska Native, Mixed, and Native Hawaiian or Pacific Islander or Indigenous Australians
Key Sponsor Type Industry Sponsors and Institutional Sponsors
Key Therapy Areas Oncology, Central Nervous System, Infectious Diseases, Cardiovascular Diseases, and Metabolic Disorders
Key Companies GSK, Johnson & Johnson, F.Hoffmann – La Roche, AbbVie, and Others

Scope

The clinical trials data used for these analyses was extracted from GlobalData’s Clinical Trials Database, captured on June 16 and July 19, 2022. The data primarily includes clinical trials initiated from January 1, 2013 to June 16, 2022. Disclosed racial representation data has been analyzed by location, by year, phase, therapy area, sponsor type, top industry sponsors, pivotal study status, single country and multinational trials, decentralized trials, and CRO involvement. Additional analysis on obstacles in the recruitment of diverse subject populations in clinical trials and steps which can be taken to increase diversity have also been included.

Reasons to Buy

  • Provides a breakdown of racial representation data across a number of clinical trial sectors.
  • Identifies which areas are lacking in clinical trial population diversity.
  • Highlights the variation in diversity in the industry and against institutional sponsors.
  • Documents the barriers to diversity in clinical trials and outlines steps to improve it.
  • Assesses how decentralized and virtual components in clinical trials affect diversity.

Novartis
GSK
Pfizer
Johnson & Johnson
AstraZeneca
F. Hoffmann-La Roche
Eli Lilly
Merck & Co
AbbVie
Bayer

Table of Contents

Executive Summary

Introduction

Analysis of Diversity in Clinical Trials (2013–2022)

Key Findings

Appendix

Figures

Figure 1: Percentage of clinical trials with disclosed racial representation data by region

Figure 2: Percentage of clinical trials with disclosed racial representation data in the top 10

countries for clinical research

Figure 3: Total representation of studies with racial demographic data

Figure 4: Racial representation in clinical trials by year

Figure 5: Proportional race representation in clinical trials by year

Figure 6: Racial demographic distribution by phase

Figure 7: Industry sponsors vs. institutional sponsors clinical trials racial representation

Figure 8: Racial representation in the top five therapy areas

Figure 9: Proportional racial representation of top company-sponsored trials

Figure 10: Racial representation in pivotal clinical trials

Figure 11: Racial representation of single country vs. multinational clinical trials

Figure 12: Racial representation of decentralized clinical trials vs. traditional trials

Figure 13: Racial representation of clinical trials with CRO involvement

Figure 14: Obstacles to clinical trial diversity

Figure 15: Increasing diversity in clinical trials

Frequently asked questions

Clinical Trials – The Importance of Diversity in Clinical Trials standard reports
Currency USD
$695

Can be used by individual purchaser only

$1,390

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Clinical Trials – The Importance of Diversity in Clinical Trials was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Clinical Trials – The Importance of Diversity in Clinical Trials in real time.

  • Access a live Clinical Trials – The Importance of Diversity in Clinical Trials dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.